Newsfeeds - Spark Newswire

2 minute read

Novavax Announces Co.’s COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial

Today, 1:45 PM

Novavax, Inc. (NASDAQ:NVAX), today announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, demonstrated 100% protection against moderate and severe disease, 90.4% efficacy overall, and

NVAX

4 minute read

FDA
News

Novavax Highlights Data From 3 Complementary Studies Of COVID-19 Beta Variant Strain Vaccine

By Benzinga Newsdesk

Today, 1:45 PM

- Recombinant spike protein antigen (rS-B.1.351) based on the Beta (B.1.351) virus lineage highly immunogenic in mice and produced neutralizing antibodies - Primates boosted with rS-B.1.351 induced strong neutralizing

NVAX

1 minute read

White House Says Will Allocate ~19M COVID-19 Vaccine Doses To Be Shared Through Covax

By Benzinga Newsdesk

Today, 1:45 PM

-Reuters

AZN

5 minute read

66 Biggest Movers From Yesterday

By Lisa Levin

Today, 1:45 PM

Gainers

AMC

5 minute read

Uncategorized

The Daily Biotech Pulse: Pfizer In Vaccine Supply Talks With India, Provention In Focus Ahead Of Briefing Doc, NeuroRx To List Via SPAC Deal

By Shanthi Rexaline

Today, 1:45 PM

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 24)

ADVM

1 minute read

Uncategorized

Novavax Says Mix-And-Match COVID-19 Vaccine Booster Trial In UK To Begin During First Week Of Jun., Trial Will Be Receiving Support From UK Gov’t. Vaccines Task Force

By Benzinga Newsdesk

Today, 1:45 PM

-Reuters

NVAX

1 minute read

Uncategorized

From Axios Event: National Institutes For Health’s Dr. Fauci Says ‘We Will Almost Certainly Require A COVID-19 Booster Shot Within A Year Or So After Getting Primary Shot

By Benzinga Newsdesk

Today, 1:45 PM

-Bloomberg

AZN

1 minute read

Uncategorized

‘G20 snubs COVID patent waiver, waters down pledge on WHO’s funding’ -Reuters Report

By Benzinga Newsdesk

Today, 1:45 PM

https://www.reuters.com/business/healthcare-pharmaceuticals/exclusive-g20-snubs-covid-patent-waiver-waters-down-pledge-whos-funding-draft-2021-05-18/?taid=60a3b800ee4f3e0001b3aad8&utm_campaign=trueAnthem:+Trending+Co

AZN

2 minute read

Uncategorized

The Week Ahead In Biotech: Sanofi, Bristol-Myers Squibb Await FDA Decisions, Earnings News Flow Tapers Off

By Shanthi Rexaline

Today, 1:45 PM

Biotech stocks had a volatile ride in the week ended May 14, with stocks moving broadly lower for much of the week before coming back up strongly in the final session. Some of the weakness may be traced back to the across-the-board weakness in markets, as macroeconomic fears unnerved traders.

ACRX